S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NASDAQ:RDUS

Radius Health - RDUS Stock Forecast, Price & News

$10.08
-0.02 (-0.20%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$10.06
$10.18
50-Day Range
$6.58
$10.84
52-Week Range
$4.97
$23.00
Volume
6.48 million shs
Average Volume
1.17 million shs
Market Capitalization
$479.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.60

Radius Health MarketRank™ Forecast

Analyst Rating
Hold
1.80 Rating Score
Upside/​Downside
14.7% Downside
$8.60 Price Target
Short Interest
Healthy
5.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.53
Upright™ Environmental Score
News Sentiment
0.39mentions of Radius Health in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$2.70 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.18) to $0.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.57 out of 5 stars

Medical Sector

1037th out of 1,117 stocks

Pharmaceutical Preparations Industry

506th out of 550 stocks

RDUS stock logo

About Radius Health (NASDAQ:RDUS) Stock

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

Radius Health Price Performance

Radius Health stock opened at $10.10 on Friday. Radius Health has a one year low of $4.97 and a one year high of $23.00. The company's fifty day moving average price is $9.49 and its two-hundred day moving average price is $8.17.

Analyst Ratings Changes

Several equities analysts recently weighed in on RDUS shares. StockNews.com lowered shares of Radius Health from a "buy" rating to a "hold" rating in a report on Tuesday. The Goldman Sachs Group decreased their price target on Radius Health from $9.00 to $8.00 and set a "neutral" rating for the company in a research note on Tuesday, May 24th. SVB Leerink raised their price target on shares of Radius Health from $7.00 to $10.00 and gave the stock a "market perform" rating in a research report on Friday, June 24th. Finally, Bank of America raised Radius Health from an "underperform" rating to a "neutral" rating and set a $8.00 target price on the stock in a research report on Wednesday, June 8th. One research analyst has rated the stock with a sell rating and five have assigned a hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $8.60.

Insider Buying and Selling at Radius Health

In other news, major shareholder Target N. V. Biotech acquired 477,824 shares of the firm's stock in a transaction that occurred on Wednesday, May 18th. The stock was acquired at an average cost of $5.57 per share, with a total value of $2,661,479.68. Following the acquisition, the insider now owns 8,733,538 shares in the company, valued at $48,645,806.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Radius Health news, major shareholder Target N. V. Biotech purchased 477,824 shares of the company's stock in a transaction on Wednesday, May 18th. The shares were bought at an average cost of $5.57 per share, with a total value of $2,661,479.68. Following the transaction, the insider now directly owns 8,733,538 shares in the company, valued at approximately $48,645,806.66. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Rubric Capital Management Lp acquired 4,012 shares of Radius Health stock in a transaction dated Wednesday, August 10th. The stock was acquired at an average cost of $10.07 per share, with a total value of $40,400.84. Following the completion of the transaction, the insider now directly owns 6,963,317 shares of the company's stock, valued at approximately $70,120,602.19. The disclosure for this purchase can be found here. Corporate insiders own 1.73% of the company's stock.

Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Stock News Headlines

Radius Health (NASDAQ:RDUS) Lifted to "Buy" at StockNews.com
StockNews.com Downgrades Radius Health (NASDAQ:RDUS) to Hold
Golden Age Of Merger Arb: Radius
Short Volatility Alert: Radius Health, Inc.
4 Analysts Have This to Say About Radius Health
See More Headlines
Receive RDUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Radius Health and its competitors with MarketBeat's FREE daily newsletter.

RDUS Company Calendar

Last Earnings
11/08/2021
Today
8/12/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RDUS
Employees
293
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.60
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
-14.7%
Consensus Rating
Hold
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Net Income
$-70,180,000.00
Pretax Margin
-30.73%

Debt

Sales & Book Value

Annual Sales
$229.97 million
Book Value
($5.74) per share

Miscellaneous

Free Float
46,777,000
Market Cap
$479.81 million
Optionable
Optionable
Beta
0.51

Key Executives

  • Mr. G. Kelly Martin (Age 63)
    CEO, Pres & Director
    Comp: $600.48k
  • Ms. Danielle Holtschlag (Age 44)
    VP of Sales & Head of U.S. Sales Channels
    Comp: $299.3k
  • Ms. Chhaya Shah (Age 58)
    Sr. VP & Chief Bus. Officer
    Comp: $631.62k
  • Dr. Stavros C. Manolagas
    Founder & Member of the Scientific Advisory Board
  • Dr. John Thomas Potts Jr. (Age 90)
    DSc, M.D., Founder & Member of the Scientific Advisory Board
  • Dr. Michael Rosenblatt M.D. (Age 74)
    Founder, Board Observer & Member of Scientific Advisory Board
  • Dr. John A. Katzenellenbogen
    Founder & Member of the Scientific Advisory Board
  • Mr. Mark William Conley CPA (Age 60)
    VP, CFO, Principal Accounting Officer & Treasurer
  • Mr. Peter A. Schwartzman
    Head of Corp. Fin.
  • Ethan Holdaway
    Head of Investor Relations













RDUS Stock - Frequently Asked Questions

Should I buy or sell Radius Health stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 1 sell rating and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RDUS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDUS, but not buy additional shares or sell existing shares.
View RDUS analyst ratings
or view top-rated stocks.

What is Radius Health's stock price forecast for 2022?

5 brokerages have issued 12-month price targets for Radius Health's stock. Their RDUS share price forecasts range from $7.00 to $10.00. On average, they predict the company's stock price to reach $8.60 in the next twelve months. This suggests that the stock has a possible downside of 14.9%.
View analysts price targets for RDUS
or view top-rated stocks among Wall Street analysts.

How have RDUS shares performed in 2022?

Radius Health's stock was trading at $6.92 at the beginning of 2022. Since then, RDUS stock has increased by 46.0% and is now trading at $10.10.
View the best growth stocks for 2022 here
.

When is Radius Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RDUS earnings forecast
.

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) posted its quarterly earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by $0.20. The biopharmaceutical company earned $56.81 million during the quarter, compared to analyst estimates of $61.40 million. During the same quarter in the previous year, the company posted ($0.14) earnings per share.

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Exact Sciences (EXAS), Cara Therapeutics (CARA), OPKO Health (OPK), Portola Pharmaceuticals (PTLA), Micron Technology (MU) and Netflix (NFLX).

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a number of retail and institutional investors. Top institutional investors include UBS Group AG (2.95%), Alpine Associates Management Inc. (2.48%), Assenagon Asset Management S.A. (1.65%), Pictet Asset Management SA (0.94%), JPMorgan Chase & Co. (0.49%) and Rafferty Asset Management LLC (0.25%). Insiders that own company stock include Growth N V Biotech, James George Chopas, Rubric Capital Management Lp and Target N V Biotech.
View institutional ownership trends
.

How do I buy shares of Radius Health?

Shares of RDUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $10.10.

How much money does Radius Health make?

Radius Health (NASDAQ:RDUS) has a market capitalization of $480.96 million and generates $229.97 million in revenue each year. The biopharmaceutical company earns $-70,180,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis.

How many employees does Radius Health have?

The company employs 293 workers across the globe.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.radiuspharm.com. The biopharmaceutical company can be reached via phone at (617) 551-4000, via email at bryan@radiuspharm.com, or via fax at 617-551-4701.

This page (NASDAQ:RDUS) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.